Dr. Reddy's Laboratories Ltd ADR Dossier
Qualitative Analysis
Business overview
Dr. Reddy's Laboratories Ltd. (NYSE: RDY, NSE: DRREDDY) is a leading global pharmaceutical company headquartered in Hyderabad, India. The company operates across multiple therapeutic segments, specializing in generics, active pharmaceutical ingredients (APIs), biosimilars, and custom pharmaceutical services. Dr. Reddy's has a strong international footprint, generating approximately 40% of its generic revenues from North America, with other key markets being India (20%), Europe (20%), and Russia & CIS. To mitigate pricing erosion in simple small-molecule oral generics, the company has strategically shifted its pipeline toward complex generics, including injectables, and biosimilars.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting towards the lucrative GLP-1 market with the strategic launch of generic Semaglutide (gOzempic) in Canada, India, and Brazil.
Expected impact: Expected to generate up to USD 200 million in revenue in FY2027, serving as a critical growth lever to offset generic erosion.
Developing a robust pipeline of advanced biosimilars, including Rituximab, Denosumab, and Abatacept, to build a long-term global biologics platform.
Expected impact: Establishes a highly specialized, high-margin revenue stream in global markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Haleon's global portfolio of Nicotine Replacement Therapy (NRT) brands (including Nicotinell, Nicabate, Habitrol, and Thrive) outside of the United States.
Financial impact: The acquired portfolio represented net revenue of GBP 217 million for the year ended December 31, 2023, and has supported top-line momentum in Europe and other international markets.
Acquisition of the trademarks and related assets of leading hormone replacement therapy (HRT) brands Progynova and Cyclo-Progynova for the Indian market.
Financial impact: Strengthens the gynecology portfolio in India; the brands recorded sales of approximately INR 100 crore (IQVIA MAT December 2025).
Strategic Partnerships
Exclusive rights to promote and distribute Sanofi's vaccine brands (including Hexaxim, Pentaxim, Tetraxim) and the novel RSV monoclonal antibody Beyfortus (nirsevimab) in India.
Terms: Sanofi's vaccine brands saw combined sales of approximately INR 426 crores (USD 51 million) as of IQVIA MAT February 2024.
Forming a joint venture (headquartered in Hyderabad) to bring innovative nutraceutical and medical nutrition brands (such as Nature's Bounty, Osteo Bi-Flex, Rebalanz, and Celevida) to consumers in India.
Terms: Dr. Reddy's made an initial investment of INR 7.34 billion (holding a 51% stake), while Nestle India invested INR 7.06 billion (holding a 49% stake).